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S U M M A R Y
Mycoplasma hominis and Ureaplasma parvum are rare causes of severe and fatal infections. The diagnosis
of infection with mycoplasma is dependent on clinical suspicion and microbiological diagnosis, and
often relies on molecular methods that do not readily detect antibiotic resistance. This may be of
increasing importance as illustrated in the case below.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Mycoplasmas can occasionally cause severe infections in both
immunocompromised and immune competent individuals, how-
ever their identiﬁcation in clinical specimens is hindered by the
fact that routine microbiological methods fail to detect this group
of pathogens. With the advent of molecular biological methods of
detecting organisms, such as eubacterial PCR, identiﬁcation of
mycoplasmas as pathogens has becomemore likely. Unfortunately
such methods do not routinely allow the detection of antibiotic
resistance. In addition infections due to these organisms are
generally not acute and dramatic in presentation, due to the
relatively low virulence of the bacteria, and thus the insidious
nature of the infection may be lost in the larger picture of
complicated cases. This case illustrates many of these features and
will hopefully serve to increase the awareness of mycoplasmas as
causes of infections, which may be severe, in difﬁcult or
complicated cases.* Corresponding author. Tel.: +49 (0)211 81 12490; fax: +49 (0)211 81 01512490.
E-mail address: colin.mackenzie@uni-duesseldorf.de (C.R. MacKenzie).
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A 54-year-old male patient was admitted to the orthopedic
department of the university clinic of Heinrich-Heine-University,
Du¨sseldorf in December 2007 with symptoms of a septic arthritis
in both knees and hips and delayed wound healing and ﬁstula
formation after implantation of a total hip prosthesis one month
before. Non-Hodgkin lymphoma (NHL), World Health Organiza-
tion grade 1, was ﬁrst diagnosed in 2006/2007 and the patient was
in remission at the time of admission. Maintenance therapy with
rituximab 750 mg/3 months had been administered until August
2007.
An arthroscopy of the left knee revealed an effusion, cultures of
which remained negative, and the patient was treated empirically
with ciproﬂoxacin and clindamycin; this was subsequently
changed to cefazolin and clindamycin, which was continued for
4 weeks. A full blood count at the time of admission revealed
leukocytes of 6.9  109/l, hemoglobin of 8.6 g/dl, and C-reactive
protein (CRP) of 37.4 mg/dl (normal value<0.5 mg/dl). Therewas a
marked hypoimmunoglobulinemia (IgG 630 mg/dl, IgA 49 mg/dl,
and IgM 29 mg/dl; normal ranges are 700–1600 mg/dl, 70–
400 mg/dl, and 40–230 mg/dl, respectively).
At the time of admission, Gram stain of a swab taken from the
non-healing wound of the right hip showed rare leukocytes but noses. Published by Elsevier Ltd. All rights reserved.
Table 1
Minimum inhibitory concentration and ﬂuoroquinolone resistance markers of Mycoplasma hominis isolate 2565
MIC (mg/ml) Amino acid change in QRDR of M. hominis GyrA, ParC, and
ParE residuesa
Strain LIN CLI MXF CIP GyrA ParC ParE
PG21b (2–8)c <1 <1 1 Ser-83 Glu-84 Val-411
Lys-134
FBGd 256 64 16–32 32 Ser-83 Glu-84 Val-411! Ile
Lys-134!Arg
2565 256 >10 000 64–128 256–512 Ser-83! Leu Glu-84!Gly Val-411! Ile
Lys-134!Arg
MIC, minimum inhibitory concentration; QRDR, quinolone resistance determining region; LIN, linezolid; CLI, clindamycin, MXF, moxiﬂoxacin, CIP, ciproﬂoxacin.
a M. hominis GyrA, ParC, and ParE residues are numbered according to the coordinates for Escherichia coli GyrA, ParC, and ParE.
b Data from Be´be´ar et al.3 and Pereyre et al.1
c Range of 24M. hominis strains tested.4
d Clinical isolate of Mycoplasma hominis characterized by Henrich et al. in 1993.5
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explored and a biopsy of the inﬂamed tissue revealed no bacteria
on Gram staining, and both aerobe and anaerobe cultures showed
no growth after 14 days. A single subsequent aspirate of the knee
grew propionibacteria and Staphylococcus epidermidis. The cultures
were considered to be contaminations of the normal skin ﬂora and
not clinically relevant as they were not reproducible. No
improvement with the treatment was observed and further
cultures (including anaerobes and mycobacteria) of drain secre-
tions remained unsuccessful.
In January 2008, whilst in the orthopedic department, the
patient developed abdominal symptoms compatible with a
ruptured infrarenal abdominal aortic aneurysm, which required
emergent resection and placement of a prosthesis. Histopatholog-
ical examination of the resected aneurysm and adventitial fat
tissue showed a chronic inﬂammatory inﬁltration composed of
ﬁbrin, lymphocytes, and macrophages, compatible with a mycotic
aneurysm. Culture of the resected aorta and blood cultures grewno
organisms and serologywas unhelpful. The subsequent course was
marked by chronically raised inﬂammatory parameters and fever,
and the antibiotic treatment was changed to moxiﬂoxacin and
rifampin for a presumed chronic S. epidermidis infection. In
February 2008 the patient developed an acute abdomen requiring
emergency laparotomy inwhich adhesions in the abdominal cavity
were released and a chronically inﬂamed appendix was removed,
although this was not thought to be the source of the infection.
The patient’s condition slowly deteriorated and infection of the
aorta prosthesis was suspected, leading to a renewed laparotomy
and replacement of the abdominal aorta prosthesis with a silver-
impregnated prosthesis. The patient was admitted post-surgery to
the surgical intensive care unit where his course was marked by
progressive deterioration of his general condition and clouding of
the level of consciousness. Computed cranial tomography showed
non-speciﬁc changes in the cerebral cortex without hard evidence
of infection or space occupying lesions.
Since aerobe and anaerobe cultures of the aortal tissue
remained sterile, DNA of this tissue was prepared for 16S-based
ampliﬁcation of eubacterial DNA. Using the 16S primer pairs 16S-
27f (50-AGAGTTTGATCNTGGYTCAG-30) and 16S-519r (50-GWAT-
TACCGCRGCKGCTG-30) in a conventional PCR of DNA extracted
from aorta tissue, a 500-bp PCR product was ampliﬁed and
sequenced on an ABI 373 A machine. A homology search carried
out by BLAST analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
revealed Mycoplasma hominis.
An in-housemultiplex real-time PCR forM. hominis,Ureaplasma
urealyticum, and Ureaplasma parvum was subsequently performed
and was positive for bothM. hominis (108 copies/mg tissue) and U.
parvum (8  104 copies/mg tissue). A number of blood cultures,
swabs, and hip tissuewere available for examination andwere alsopositive in PCR for M. hominis and U. parvum. In total four
specimens collected from the hip (including a biopsy) grew M.
hominis and were also positive for U. parvum DNA. Four blood
culture bottles were positive for M. hominis. Treatment with
moxiﬂoxacin was initiated, however the patient’s condition
continued to deteriorate and a presumed nosocomial infection
was treated with meropenem and linezolid. Approximately 14
days later the patient developed septic shock and resuscitationwas
unsuccessful. Permission for autopsy was not granted.
3. Discussion
Wehave described the case of an immunocompromised patient
who developed a disseminated infectionwith two organisms of the
Mycoplasma genus, M. hominis and U. parvum, which ultimately
lead to his death. Both organisms represent a challenge for the
medical microbiologist and infectious disease specialist due to
difﬁculties in diagnosing the bacterial infection. The reasons for
this are manifold: for the clinician the relatively low virulence of
the organisms and a paucity of recorded casesmeans that there is a
low index of suspicion for these organisms. The inability to detect
mycoplasmas by Gram-staining and atypical or absent growth on
the standardmedia contribute to the failure of routine detection in
the microbiology laboratory. None of the mycoplasmas are readily
detected by standard microbiology methods in the laboratory,
although the human pathogenic mycoplasmas are fairly easy to
grow in the correct media and conditions.
We examined all the available specimens for the presence of
both mycoplasmas using the quantitative real-time PCR. A
consistently higher bacterial count was found for M. hominis in
all tissues than for U. parvum, and very high bacterial concentra-
tions were found in all tissues examined.
Interesting in this case is the empiric antibiotic therapy and
susceptibilities of the organisms.M. hominis is, in contrast to most
mycoplasmas, intrinsically resistant to macrolide antibiotics due
to mutations in the 23S rRNA gene1 and is the only mycoplasma
susceptible to clindamycin. In this patient clindamycin was
administered over many weeks as empiric therapy for an infected
hip prosthesis. Clindamycin therapy has been reported to be
successful for a number of similar infections due toM. hominis and
thus should have been adequate to treat theM. hominis infection in
this patient.2 In addition to clindamycin, ciproﬂoxacin was
administered on more than one occasion, which is also generally
a good choice for mycoplasma eradication. In view of this we
analyzed the sensitivity of the M. hominis isolate to different
antibiotics in culture and the antibiotic resistance markers at a
molecular level (see Table 1). Mutations were found within the
quinolone resistance determining region (QRDR) of GyrA, ParC, and
ParE with regard to the published type strain of M. hominis, PG21
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hominis isolate 2565 , from this patient, was determined by broth
microdilution; the results compared to other values found in the
literature are shown in Table 1.4 The antibiotic sensitivity of a
laboratory strain, FBG,5 was tested in parallel. The strain isolated in
the case presented here showed a marked resistance to linezolid,
the ﬂuoroquinolones moxiﬂoxacin and ciproﬂoxacin, and also to
clindamycin. A very high level of resistance to clindamycin was
detected, >10 000 mg/ml. The basis of the ﬂuoroquinolone
resistance was shown to be due to mutations in the GyrA, ParC,
and ParE proteins. Interestingly the sequences of GyrA, GyrB, ParC,
and ParE proteins of the U. parvum isolate correspond to those of
serovar 3.3 Unfortunately we were unable to grow the U. parvum
strain in pure culture and thus were not able to determine the MIC
for ciproﬂoxacin.
There are a number of reports in the literature concerning
disseminated infections with mycoplasma and also of the growth
of M. hominis in standard blood culture bottles, although the
automatic detection systems fail to report growth and thus the
cultures are generally discarded and reported as no growth.6 There
are four previous cases of mycoplasma-infected aneurysms or
grafts in the literature and thesewere reported on and summarized
by Fenollar et al.7,8,9 In these cases infection was caused either by
M. hominis or U. urealyticum, not by both as in the case reported
here. Furthermore a series of pulmonary infectionswithM. hominis
in intensive care patients has been reported, which further
emphasizes the failure of the usual empiric antibiotic therapy to
treat mycoplasmas.10 A further case of a fatal infection caused by
both M. hominis and U. urealyticum was published in 2008, in this
case a post-sternotomy infection.11 Both this case and ours
demonstrate that the mycoplasmas cause serious infections, not
only in low birth weight neonates, but also in adults. The patient in
this case was immunocompromised in that he had NHL, in
remission, and was, until admission, under maintenance therapy
with rituximab. Throughout the hospital course, the leukocytes
were never raised and in fact were periodically at or just below the
lower limit of normal, despite obvious signs of infection including
fever and raised CRP. In addition the patient had a marked
hypogammaglobulinemia, which has been reported to be one of
four risk factors for Mycoplasma septic arthritis: (1) hypogam-
maglobulinemia, (2) immunocompromised state, (3) postpartum
or post-abortion fever, and (4) urinary tract manipulation.12 This
patient had at least two of the four; it is not knownwhether he had
any urinary tract manipulation prior to admission to this hospital.
The immune suppression most probably played a role in the
infection, however, as can be seen in the previous reports, an
obvious immune defect is not necessarily a prerequisite for a fatal
mycoplasma infection.11 An asymptomatic bacteremia with both
organisms at the time of the original hip replacement is possible,
which may have led to the post-surgical infection, eventually
resulting in his admission to this clinic.The patient acquired a post-operative infection of his hip
prosthesis due to M. hominis and U. parvum, which culminated
over the course of several months in a disseminated infection and
mycotic aneurysm, ultimately leading to the death of the patient. At
no time in the course of the illness in this clinic was any other
plausible organism isolated from any specimen and there was no
response to empiric therapy. It is an added tragedy in this case that
theM. hominiswas highly resistant to the empiric clindamycin and
ciproﬂoxacin therapy. Thus in conclusion, it is not only important for
clinicians and clinical microbiologists to consider mycoplasmas as
possible pathogens in cases of otherwise culture-negative infec-
tions, but also to consider the possibility that themycoplasmasmay
be or become resistant to the usual antibiotics used to combat them.
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